This is a StreetInsider.com Premium Only Page

Provention Bio Inc. (PRVB) – StreetInsider.com Reports

Mar 15, 2023 06:20 AM H.C. Wainwright Downgrades Provention Bio Inc. (PRVB) to Neutral

Mar 14, 2023 03:19 AM Jefferies Downgrades Provention Bio Inc. (PRVB) to Hold

Mar 13, 2023 04:05 PM SMBC Nikko Securities Downgrades Provention Bio Inc. (PRVB) to Neutral

Mar 13, 2023 11:44 AM Sanofi agrees to $2.9B purchase of Provention Bio in bid to boost diabetes drug

Mar 13, 2023 10:13 AM Cantor Fitzgerald Downgrades Provention Bio Inc. (PRVB) to Neutral

Mar 13, 2023 06:56 AM Sanofi (SNY) Acquires Provention Bio (PRVB) for $25/share in cash, or $2.9 billion

Mar 10, 2023 04:18 AM Options with decreasing option implied volatility: PRVB AMC MDB SAVE SE NTNX ASAN

Feb 15, 2023 06:42 AM Provention Bio Inc. (PRVB) PT Lowered to $16 at H.C. Wainwright

Jan 17, 2023 11:51 AM Provention Bio Inc. (PRVB) Tzield at to VA drug catalog

Jan 5, 2023 04:01 PM Provention Bio Inc. (PRVB) Appoints Rita Jain to its Board

Nov 21, 2022 08:00 AM Provention Bio Inc. (PRVB) PT Raised to $22 at Jefferies

Nov 18, 2022 09:14 AM Provention Bio Inc. (PRVB) PT Raised to $18 at Oppenheimer, Staying Bullish on Tzield Approval

Nov 18, 2022 08:59 AM Provention prices diabetes drug above analysts' estimates at $13,850/vial

Nov 18, 2022 08:56 AM RBC Capital on Provention Bio Inc. (PRVB): 'we believe an approval has already been priced in and we watch for the durability of share levels'

Nov 17, 2022 05:46 PM Provention Bio's (PRVB) TZIELD Approved by FDA to Delay Onset of Stage 3 Type 1 Diabetes

Nov 17, 2022 05:05 PM FDA Approves Provention Bio's (PRVB) Drug That Can Delay Onset of Type 1 Diabetes

Nov 17, 2022 04:25 PM Provention Bio Inc. (PRVB) Halted, News Pending

Nov 4, 2022 06:33 AM Provention Bio Inc. (PRVB) PT Raised to $9 at RBC Capital

Oct 7, 2022 08:00 AM UPDATE: Provention Bio Inc. (PRVB) PT Raised to $15 at Jefferies

Oct 6, 2022 08:13 AM Provention Bio Inc. (PRVB) to Combine Forces with Sanofi (SNY) to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes

Sep 20, 2022 07:45 AM UPDATE: Jefferies Starts Provention Bio Inc. (PRVB) at Buy, $10 PT

Aug 8, 2022 08:42 AM Provention Bio Inc. (PRVB) PT Lowered to $14 at Oppenheimer

Aug 4, 2022 07:33 AM Provention Bio Inc. (PRVB) Tops Q2 EPS by 4c

Jul 29, 2022 04:29 PM Provention Bio Inc. (PRVB) Announces 13.32M Share Offering by Selling Stockholders

Jul 25, 2022 07:15 AM Provention Bio Inc. (PRVB) Announces 13.32M Share Offering by Selling Stockholders

Jul 11, 2022 06:32 AM Provention Bio Inc. (PRVB) PT Lowered to $18 at H.C. Wainwright

Jun 30, 2022 04:01 PM Provention Bio Inc. (PRVB) Announces Extension of FDA User Fee Goal Date for Teplizumab to November 17, 2022

Jun 3, 2022 07:03 AM Provention Bio Inc. (PRVB) Announces Board Changes

May 5, 2022 07:49 AM Provention Bio Inc. (PRVB) Tops Q1 EPS by 11c

May 5, 2022 07:05 AM Provention Bio Inc. (PRVB) Reports Q1 Results, Provides Business Update

Apr 28, 2022 06:05 AM Cantor Fitzgerald Assumes Provention Bio Inc. (PRVB) at Overweight

Mar 28, 2022 07:31 AM Provention Bio Inc. (PRVB) Reports Positive Final Results from Study of Coxsackievirus B Vaccine Candidate PRV-101

Mar 21, 2022 07:02 AM Provention Bio Inc. (PRVB) Announces FDA Acceptance of the BLA Resubmission for Teplizumab for the Delay of Clinical Type 1 Diabetes in At-Risk Individuals

Feb 24, 2022 07:20 AM Provention Bio Inc. (PRVB) Tops Q4 EPS by 4c

Feb 22, 2022 07:33 AM Provention Bio Inc. (PRVB) Announces BLA Resubmission for Teplizumab to Address CRL

Jan 28, 2022 09:21 AM Pre-Open Stock Movers 01/28: (CLFD) (PRVB) (TEAM) Higher; (HOOD) (WDC) (CVX) Lower (more...)

Jan 27, 2022 04:05 PM Provention Bio Inc. (PRVB) is Resubmitting BLA for Delay of Clinical Type 1 Diabetes in At-Risk Individuals Following Type B Meeting with the FDA

Dec 20, 2021 07:35 AM Provention Bio Inc. (PRVB) Expands Leadership Team

Nov 22, 2021 07:31 AM Provention Bio Inc. (PRVB) Issues Regulatory Update for Teplizumab At-Risk Type 1 Diabetes Approval Pathway

Nov 4, 2021 07:53 AM Provention Bio Inc. (PRVB) Tops Q3 EPS by 8c

Nov 4, 2021 07:07 AM Provention Bio Inc. (PRVB) Appoints Thierry Chauche as CFO

Oct 26, 2021 07:35 AM Provention Bio Inc. (PRVB) Announces Positive Interim Results from First-In-Human Study of Coxsackievirus B Vaccine Candidate PRV-101

Sep 13, 2021 07:35 AM Provention Bio (PRVB) Provides Update on Potential Timing of Teplizumab At-Risk Type 1 Diabetes Biologics License Application Resubmission

Aug 6, 2021 05:20 AM Provention Bio Inc. (PRVB) PT Lowered to $16 at Oppenheimer

Jul 12, 2021 07:01 AM Provention Bio Inc's. (PRVB) Teplizumab Awarded Innovation Passport in the UK

Jul 6, 2021 01:19 PM Provention Bio (PRVB) Plunges Following CRL for Teplizumab in Type 1 Diabetes

Jul 6, 2021 09:30 AM Pre-Open Stock Movers 07/06: (ADXS) (AXLA) (WB) Higher; (PRVB) (DIDI) (LLNW) Lower (more...)

Jul 6, 2021 07:11 AM Provention Bio (PRVB) to Resume Trading at 7:30 a.m.

Jul 6, 2021 07:00 AM Provention Bio Inc. (PRVB) Receives CRL to BLA for Teplizumab for Delay of Clinical Type 1 Diabetes (T1D) in At-risk Individuals

Jul 6, 2021 06:55 AM Provention Bio Inc. (PRVB) Halted, News Pending